Physician profile
Christopher E Lacroix
NPI 1669437984
$1,045.53
in general payments reported to CMS, 2019-2025
19 companies · $42.96 in 2025
The $42.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $323 · 2021: $13.77 · 2022: $120 · 2023: $155 · 2024: $269 · 2025: $42.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $209.31 | 2020-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $182.66 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $90.16 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Merz North America, INC. | $83.40 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $59.77 | 2019-2022 | |
| Abbvie INC. | $45.08 | 2019-2024 | |
| Covidien Lp | $38.47 | 2020 | |
| Lilly USA, LLC | $29.96 | 2022-2023 | Mounjaro |
| Allergan, INC. | $25.11 | 2020 | |
| Medtronic Vascular, INC. | $23.01 | 2019 | |
| Corium, LLC | $21.89 | 2023 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $21.20 | 2023 | Evkeeza |
| Takeda Pharmaceuticals U.S.A., INC. | $20.68 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.23 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.63 | 2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $15.04 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lacroix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.